Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Prevalence of the CHEK2 R95* germline mutation.

Knappskog S, Leirvaag B, Gansmo LB, Romundstad P, Hveem K, Vatten L, Lønning PE.

Hered Cancer Clin Pract. 2016 Sep 27;14:19. eCollection 2016.

2.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

3.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

4.
5.
6.

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.

Helle SI, Geisler J, Anker GB, Leirvaag B, Holly JM, Lønning PE.

Br J Cancer. 2001 Jul 20;85(2):147-51.

7.

Effect of spermidine on the activation of homocysteine.

Leirvaag B, Strand I, Abraham AK.

Biochem Soc Trans. 1998 Nov;26(4):S374. No abstract available.

PMID:
10047888

Supplemental Content

Loading ...
Support Center